PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Moreau, P. [1 ]
Chanan-Khan, A. [2 ]
Roberts, A. W. [3 ]
Agarwal, A. [4 ]
Facon, T. [5 ]
Kumar, S. [2 ]
Touzeau, C. [1 ]
Diehl, S. [6 ]
Cordero, J. [6 ]
Ross, J. [6 ]
Munasinghe, W. [6 ]
Zhu, M. [6 ]
Salem, A. H. [6 ]
Leverson, J. [6 ]
Maciag, P. [6 ]
Verdugo, M. [6 ]
Harrison, S. J. [7 ]
机构：
[1] CHU Nantes, Hotel Dieu HME, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ Arizona, Ctr Canc, Tucson, AZ USA
[5] Hop Huriez, CHRU Lille, Lille, France
[6] AbbVie Inc, N Chicago, IL USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P272
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [41] Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, plus /- bortezomib, in patients with relapsed/refractory multiple myeloma.
    Kaufman, Jonathan L.
    Baz, Rachid C.
    Harrison, Simon J.
    Quach, Hang
    Ho, Shir-Jing
    Vangsted, Annette J.
    Moreau, Philippe
    Gibbs, Simon D. J.
    Salem, Ahmed H.
    Coppola, Sheryl
    Ross, Jeremy A.
    Masud, Abdullah A.
    Westrup, Sally
    Vue, Jenny
    Maciag, Paulo Cesar
    Bueno, Orlando
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
  • [43] PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
    Palumbo, A.
    Chanan-Khan, A.
    Weisel, K.
    Nooka, A. K.
    Masszi, T.
    Beksac, M.
    Spicka, I.
    Hungria, V.
    Munder, M.
    Mateos, M. V.
    Mark, T.
    Qi, M.
    Schecter, J.
    Amin, H.
    Qin, X.
    Deraedt, W.
    Ahmadi, T.
    Spencer, A.
    Sonneveld, P.
    HAEMATOLOGICA, 2016, 101 : 340 - 341
  • [44] Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma
    Kaufman, Jonathan L.
    Gasparetto, Cristina J.
    Mikhael, Joseph
    Moreau, Philippe
    Touzeau, Cyrille
    Vij, Ravi
    Facon, Thierry
    Pegourie, Brigitte
    Benboubker, Lofti
    Boise, Lawrence H.
    Alzate, Stefanie
    Dunbar, Martin
    Jia, Jia
    Freise, Kevin J.
    Verdugo, Maria
    Ross, Jeremy
    Maciag, Paulo
    Kumar, Shaji K.
    BLOOD, 2017, 130
  • [45] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
    Sugiura, Isamu
    Terabe, Satomi
    Kinoshita, Tomohiro
    Yamamoto, Kazuhito
    Sawa, Masashi
    Ozawa, Yukiyasu
    Atsuta, Yoshiko
    Suzuki, Ritsuro
    Shimizu, Kazuyuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (04) : 434 - 440
  • [46] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
    Isamu Sugiura
    Satomi Terabe
    Tomohiro Kinoshita
    Kazuhito Yamamoto
    Masashi Sawa
    Yukiyasu Ozawa
    Yoshiko Atsuta
    Ritsuro Suzuki
    Kazuyuki Shimizu
    International Journal of Hematology, 2015, 102 : 434 - 440
  • [47] Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
    Kumar, Shaji K.
    LaPlant, Betsy R.
    Reeder, Craig B.
    Roy, Vivek
    Halvorson, Alese E.
    Buadi, Francis
    Gertz, Morie A.
    Bergsagel, P. Leif
    Dispenzieri, Angela
    Thompson, Melanie A.
    Crawley, Jamie
    Kapoor, Prashant
    Mikhael, Joseph
    Stewart, Keith
    Hayman, Suzanne R.
    Hwa, Yi L.
    Gonsalves, Wilson
    Witzig, Thomas E.
    Ailawadhi, Sikander
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Rivera, Candido E.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2016, 128 (20) : 2415 - 2422
  • [48] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345